Anavex receive compassionate use authorization for child patients with Rhett

Anavex Life Sciences announced that the first patients with Rett syndrome from the ANAVEX2-73-RS-003 study are able to continue treatment with ANAVEX2-73 thanks to Health Canada’s approval of the Special Access Program, allowing for compassionate use following completion of the 48-week Open-Label Extension study. Special Access Program applications are granted at a physicians’ request on behalf of patients. Based on the safety profile of ANAVEX2-73, as well as clinical evidence that the study drug will continue to benefit patients, Anavex will continue its responsibility to support patients post study by facilitating the supply of ANAVEX2-73 to patients in Canada. Christopher U Missling, PhD, President and Chief Executive Officer of Anavex said: “While our clinical studies with ANAVEX2-73 are very critical to collect clinical information for regulatory purposes, we also recognize the long-term commitment to our investigators, patients and families. Therefore, post clinical studies, we are keen to provide supply to the investigators that have requested compassionate use of ANAVEX2-73 for their patients on a global basis. In compliance with local authorities, many patients from our clinical studies are now able to continue treatment with ANAVEX2-73.”